SCHLIEREN, Switzerland--(BUSINESS WIRE)--The United States Patent and Trademark Office (USPTO) has officially granted InSphero AG full protection of its GravityPLUS™ hanging drop technology. InSphero, ...
SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSphero AG today announced that Akero has selected InSphero's 3D InSight™ Human Liver Disease Platform to ...
SCHLIEREN, Switzerland, March 24, 2020 /PRNewswire/ -- InSphero AG, the pioneer of 3D cell-based assay technology, today announced that it will offer free safety testing for exploratory COVID-19 ...
Please provide your email address to receive an email when new articles are posted on . InSphero AG announced the launch of 3D InSight Human Liver Disease Discovery Platform, a 3D cell technology for ...
SCHLIEREN, ZURICH, SWITZERLAND, February 11, 2026 /EINPresswire.com/ — InSphero AG, the global market leader in 3D cell-based assays and organ-on-chip systems ...
ZURICH, Oct. 15, 2024 /PRNewswire/ -- InSphero, the global leader in 3D cell culture technology, and scientists from the U.S. Food and Drug Administration's (FDA) National Center for Toxicological ...
InSphero, announced the acquisition of California-based PhenoVista Biosciences, Inc., a premier provider of high-content imaging and phenotypic assay technologies and services. The acquisition marks ...
The acquisition marks an important new chapter for PhenoVista Biosciences, enabling the company to significantly expand its scientific and commercial impact by combining its expertise in high-content ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results